A5043783108- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Viral-associated cancers and disorders
- Eosinophilic Disorders and Syndromes
- Neutropenia and Cancer Infections
- Lung Cancer Research Studies
- Hematological disorders and diagnostics
- Cancer Treatment and Pharmacology
- Polyomavirus and related diseases
- Hemoglobinopathies and Related Disorders
- CNS Lymphoma Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- Testicular diseases and treatments
- Lung Cancer Treatments and Mutations
- Blood transfusion and management
- Blood disorders and treatments
- Mesenchymal stem cell research
- Vascular Tumors and Angiosarcomas
- Childhood Cancer Survivors' Quality of Life
Mind Australia
2025
University of Auckland
2018-2024
University of British Columbia
2009-2020
Vancouver General Hospital
2007-2019
Leukemia & Lymphoma Society of Canada
2004-2019
BC Cancer Agency
2008-2018
Molecular Oncology (United States)
2015
University of Glasgow
2013
Cancer Research UK
2005-2013
Université de Poitiers
2013
Fifty-six consecutive patients with advanced Hodgkin's disease considered incurable further conventional chemotherapy were entered into a protocol that included high-dose cyclophosphamide (7.2 g/m2), carmustine (BCNU; 0.6 and etoposide (VP16-213; 2.4 g/m2) (CBV) followed by autologous bone marrow transplantation (BMT). Prior combination had failed in all the patients, but five been previously treated both mechlorethamine, vincristine, procarbazine, prednisone (MOPP) doxorubicin, bleomycin,...
In this report we describe a quantitative in vitro assay for the most primitive type of leukemic precursors yet defined patients with chronic myeloid leukemia (CML). This is based on recently described "long-term culture-initiating cell" (LTC-IC) normal human hematopoietic cells. Such cells, when cocultured competent fibroblast feeder layers, give rise after minimum 5 weeks to multiple single and multilineage clonogenic progenitors detectable secondary semisolid cultures. Similar cultures...
Abstract The inclusion of familial myeloid malignancies as a separate disease entity in the revised WHO classification has renewed efforts to improve recognition and management this group at risk individuals. Here we report cohort 86 acute leukemia (AML) myelodysplastic syndrome (MDS) families with 49 harboring germline variants 16 previously defined loci (57%). Whole exome sequencing further 37 uncharacterized (43%) allowed us rationalize 65 new candidate loci, including genes mutated rare...
PURPOSE: To correlate cytogenetic abnormalities with clinical presentation and outcome in Burkitt-like, small noncleaved non-Burkitt's lymphoma (SNC-NB). PATIENTS AND METHODS: Thirty-nine patients SNC-NB a clonal karyotype were evaluated between January 1989 1996. All from British Columbia, Canada, underwent uniform staging, treated on investigational protocols by group of clinicians. RESULTS: Three groups identified analysis: (1) those c-myc translocation (n = 11); (2) dual bcl-2 13); (3)...
While most myelodysplastic syndrome/acute myeloid leukemia cases are sporadic, rare familial occur and provide some insight into leukemogenesis. The clearly defined result from inherited mutations in RUNX1 or CEBPA. Recently, novel germline GATA2 have been reported. We, therefore, investigated individuals families with one more first-degree relatives wild-type CEBPA, for mutations. Screening other recurrent was also performed. A p.Thr354Met mutation observed a pedigree which 2 cousins...
Imatinib mesylate (IM) induces clinical remission of chronic myeloid leukemia (CML). The Abelson helper integration site 1 (AHI-1) oncoprotein interacts with BCR-ABL and Janus kinase 2 (JAK2) to mediate IM response primitive CML cells, but the effect interaction complex on ABL JAK2 inhibitors is unknown. AHI-1–BCR-ABL–JAK2 was analyzed by mutational analysis coimmunoprecipitation. Roles in regulation or resistance were investigated BCR-ABL+ cells primary stem/progenitor immunodeficient NSG...
Acute myeloid leukemia (AML) presenting with a high leukocyte count has been associated an increase in induction mortality and poor results number of other survival measures. However, the level at which elevated prognostic significance AML remains unclear. In this report on series 375 adult (non-M3) patients undergoing chemotherapy single institution, analyzed as continuous variable is shown to be better predictor death (ID) overall (OS) than > or = 100 x 10(9)/L, value characteristically...
In relapsing-remitting multiple sclerosis (RRMS), extended exposure to high-efficacy disease modifying therapy may increase the risk of side effects, compromise treatment adherence, and inflate medical costs. Treatment de-escalation, here defined as a switch lower efficacy therapy, is often considered by patients physicians, but evidence guide such decisions scarce. this study, we aimed compare clinical outcomes between who de-escalated versus those continued their therapy. retrospective...
Forty-four patients with relapsed or refractory aggressive histology non-Hodgkin lymphoma (NHL) (diffuse large B cell, n = 23; peripheral T 5; transformed 16) proceeded to allogeneic stem cell transplant (allo-SCT) between 1987 and 2003. Median age at was 40 years (range 19-56 years). At the time of transplant, 35 were chemosensitive nine chemorefractory. Thirty-three had matched sibling donors 11 unrelated donors. Forty-two (95%) received radiation-based conditioning regimens. Event-free...
S ummary . Between 1972 and 1982, 112 consecutive previously untreated adults (aged 15–69 years, median 26) commenced therapy for acute lymphoblastic leukaemia (ALL) at St Bartholomew's Hospital. The first 63 patients entered into the study received initial treatment which comprised four cycles of adriamycin vincristine, prednisolone L‐asparaginase with cycle (OPAL). In 1978, six were given, escalating doses cyclophosphamide from 3 (HEAV'D). Central nervous system (CNS) prophylaxis...
The retroviral restriction factor tripartite motif–containing 5α (Trim5α) acts during the early postentry stages of life cycle to block infection by a broad range retroviruses, disrupting reverse transcription and integration. mechanism this is poorly understood, but it has recently been suggested involve recruitment components autophagy machinery, including members mammalian autophagy-related 8 (ATG8) family involved in targeting proteins autophagosome. To better understand molecular...
To determine the value of skin biopsies in management suspected graft-vs-host disease (GVHD) within 30 days allogeneic bone marrow transplantation (BMT).Retrospective study based on review a BMT database.Leukemia/BMT ward tertiary care, university teaching hospital.One hundred and eighty-seven consecutive patients who received between January 1, 1994, June 30, 1997, at Vancouver General Hospital, Vancouver, British Columbia.(1) Skin biopsy frequency for with rashes suggestive acute GVHD; (2)...
To evaluate the use of reduced-intensity (RI) conditioning with allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical family donors in patients myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).Sixteen (median age, 54 years; range, 37 to 66 years) underwent RI-HSCT using a regimen fludarabine 25 mg/m2 daily for 5 days and either cyclophosphamide 1 g/m2 2 (14 patients) melphalan 140 day (two patients). The median number CD34+ cells CD3+ infused per kilogram...